Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products

Executive Summary

Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.

You may also be interested in...



Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates

Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

The company is on track to launch the first Remicade biosimilar in the US Nov. 21 using dedicated sales reps and resources from the innovative side of the business, though it will not be a traditional sales force.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel